• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Unoprostone solution now available across U.S.


Unoprostone isopropyl formulation (Rescula, Sucampo) makes alternative mechanism available for lowering IOP in open-angle glaucoma or ocular hypertension.


Bethesda, MD-Sucampo Pharmaceuticals’ formulation of unoprostone isopropyl ophthalmic solution 0.15% (Rescula) is now available by prescription across the United States, according to the company.

The FDA approved a supplemental new drug application for the big-potassium channel activator on Dec. 7, 2012 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

According to the approved product labeling, the solution may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower IOP.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.